Health Care & Life Sciences » Biotechnology | InVivo Therapeutics Holdings Corp.

InVivo Therapeutics Holdings Corp. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
740.70
752.00
689.00
553.00
395.00
91
Gross Income
740.70
752.00
689.00
553.00
395.00
91
SG&A Expense
18,264.50
17,087.00
21,709.00
23,510.00
23,300.00
12,676
EBIT
19,005.20
17,839.00
22,398.00
24,063.00
23,695.00
12,767
Unusual Expense
19,636.10
376.00
10,804.00
593.00
3,165.00
13,413
Interest Expense
129.90
136.00
172.00
155.00
74.00
43
Pretax Income
38,755.90
18,346.00
33,314.00
23,438.00
26,745.00
23,423
Consolidated Net Income
38,755.90
18,346.00
33,314.00
23,438.00
26,745.00
23,423
Net Income
38,755.90
18,346.00
33,314.00
23,438.00
26,745.00
23,423
Net Income After Extraordinaries
38,755.90
18,346.00
33,314.00
23,438.00
26,745.00
23,423
Net Income Available to Common
38,755.90
18,346.00
33,314.00
23,438.00
26,745.00
23,423
EPS (Basic)
52.00
21.00
31.50
19.00
20.25
4.69
Basic Shares Outstanding
739.90
883.20
1,058.50
1,241.00
1,318.00
4,990.10
EPS (Diluted)
52.38
20.77
31.47
18.89
20.29
4.69
Diluted Shares Outstanding
739.90
883.20
1,058.50
1,241.00
1,318.00
4,990.10
EBITDA
18,264.50
17,087.00
21,709.00
23,510.00
23,300.00
12,676
Non-Operating Interest Income
15.30
5.00
60.00
187.00
189.00
249

About InVivo Therapeutics Holdings

View Profile
Address
One Kendall Square
Cambridge Massachusetts 02139
United States
Employees -
Website http://www.invivotherapeutics.com
Updated 07/08/2019
Invivo Therapeutics Holdings Corp. operates as a research and clinical-stage biotechnology company, which engages in developing and commercializing biopolymer scaffolding devices for the treatment of SCIs. Its clinical development program is the Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord. The company was founded by Joseph P.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.